Immupharma PLC Result of AGM (5929E)

TIDMIMM

RNS Number : 5929E

Immupharma PLC

30 June 2023

RNS: RELEASE 30 June 2023

ImmuPharma PLC

("ImmuPharma" or the "Company")

2023 RESULT OF ANNUAL GENERAL MEETING - ALL RESOLUTIONS PASSED

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that all resolutions were duly passed, details of which are contained in the table below.

 
 Resolution                      For            % For   Against     % Against   Withheld 
 1. To receive the accounts 
  of the Company for the 
  year ended 31 December 
  2022 together with the 
  reports thereon of the 
  directors and auditors 
  of the Company                 52,114,317     99.08   482,400     0.92        49,317 
                                -------------  ------  ----------  ----------  ---------- 
 2. To re-appoint Dr Sanjeev 
  Pandya as a director of 
  the Company                    47,601,452     90.55   4,964,842   9.44        79,740 
                                -------------  ------  ----------  ----------  ---------- 
 3. To re-appoint CLA Evelyn 
  Partners Limited as Auditor 
  of the Company                 52,084,178     99.08   482,400     0.92        79,456 
                                -------------  ------  ----------  ----------  ---------- 
 4. That the Directors 
  be authorised for the 
  purpose of Section 551 
  of the Companies Act 2006 
  (the "Act") to allot shares 
  on the basis as set out 
  in the Notice of Meeting       51,003,388     98.86   585,640     1.14        1,057,006 
                                -------------  ------  ----------  ----------  ---------- 
 5. That the Company may 
  send or supply documents 
  or information to members 
  by making them available 
  on a website or other 
  electronic means.                52,115,217   99.08   484,400     0.92        46,417 
                                -------------  ------  ----------  ----------  ---------- 
 SPECIAL RESOLUTION 
  6. That, subject to the 
  passing of Resolution 
  4 the directors be and 
  they are hereby empowered 
  pursuant to section 571 
  of the Act to allot equity 
  securities (as defined 
  in section 560 of the 
  Act).                          51,013,053     99.88   575,975     1.12        1,057,006 
                                -------------  ------  ----------  ----------  ---------- 
 

As at the date of the AGM, the number of issued ordinary shares of the Company was 333,403,115 shares, which was the total number of shares entitling the holders to attend and vote for or against all resolutions. In accordance with the Company's Articles of Association, every member has one vote for every share held. Votes withheld are not votes in law and have not been counted in the calculation of the proportion of vote "for" or "against" a resolution. Proxy appointments which gave discretion to the Chairman have been included in the "for" total.

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

Ends

 
 For further information please contact: 
   ImmuPharma PLC ( www.immupharma.com ) 
    Tim McCarthy, Chairman and Chief Executive 
    Officer                                       [phone] 
   Lisa Baderoon, Head of Investor Relations 
    & Non-Executive Director                      + 44 (0) 7721 413496 
   SPARK Advisory Partners Limited (NOMAD) 
    Neil Baldwin                                  [phone] 
 
    Stanford Capital Partners (Joint Broker) 
    Patrick Claridge, John Howes, Bob Pountney     [phone] 
 
    SI Capital (Joint Broker) 
    Nick Emerson                                   [phone] 
 

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor(TM)), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

For additional information about ImmuPharma please visit www.immupharma .co.uk

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGMZGFVZGMGFZM

(END) Dow Jones Newswires

June 30, 2023 08:12 ET (12:12 GMT)